Early Placental Insufficiency Screening

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

226 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-05-31

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the role of uterine artery and maternal serum PlGf and sflt-1 and their combination in screening for pre-eclampsia and small -for-gestational age (SGA) fetuses at 12-14 weeks of gestation

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Doppler and Biological Second Trimester Placental Insufficiency Screening

NCT00465634

Pre-Eclampsia Fetal Growth Retardation Placental Insufficiency

COMPLETED

Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy.

NCT03455387

Pre-Eclampsia HELLP Syndrome Fetal Death +3 more

COMPLETED

sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.

NCT04766866

Preeclampsia Intrauterine Growth Restriction Maternal Hypertension +2 more

RECRUITING NA

sFlt-1/PlGF Ratio: Impact on the Management of Patients With Suspected Pre-eclampsia

NCT05228002

Pre-Eclampsia

COMPLETED NA

MorbiMortality Amelioration in Preeclamptic Primiparas Study. MoMA Pre Prim Study

NCT00763672

Pregnancy Primiparity Hypertension +2 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pre-eclampsia (PE) and intrauterine growth restriction (IUGR) are known as major factors in perinatal morbidity and mortality. Routine antenatal care is focused on the detection of women at increased risk to apply this population a program of careful monitoring and appropriate intervention.

Uterine artery Doppler during anomaly scan at 12 to 14 weeks in selected women at increased risk, has proved to be accurate to detect those who will develop PE or IUGR during the second half of pregnancy.

A variety of angiogenic proteins have been studied as potential markers for pre-eclampsia. Among these protein Plgf and sflt-1 have respectively demonstrated higher and lower levels in pregnant women who will subsequently develop pre-eclampsia.

Our study is aimed to evaluate the performance of serum Plgf and sflt-1 measurement in association with uterine artery Doppler as a screening for placental insufficiency.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-eclampsia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic hypertension under medication
* Insulin or not insulin dependant preexisting diabetes
* Previous history of pre-eclampsia
* Previous history of unexplained stillbirth
* Previous history of placental abruption
* Previous history of SGA (\< 10th centile)
* History of pre-eclampsia or chronic hypertension before 45 years in the mother or a sister
* History of vascular pathology before 50 years in the father
* Obesity (BMI\>26)
* Nulliparous after 38 years
* Assisted conception with donor
* Primipaternity after 38 years old or before 20 years old